News and Trends 3 Nov 2022
Servier and OSE Immunotherapeutics complete enrollment in Sjögren’s syndrome trial
Servier and French biotech company OSE Immunotherapeutics SA have completed patient enrollment in a phase 2a clinical trial evaluating the efficacy and safety of monoclonal antibody OSE-127/S95011 in primary Sjögren’s…